NIOSHTIC-2 Publications Search
Tier II mutagenic screening of 13 NIOSH priority compounds, individual compound report, N,N-dimethylformamide.
Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, Contract 210-78-0026, 1981 May; :1-189
N,N-Dimethylformamide (68122) (NND) was subjected to a tier II mutagenic test screening program. The assays included unscheduled DNA synthesis (UDS) assay in human diploid fibroblasts with exposure of 3 hours duration and concentrations up to 9,220 micrograms per milliliter of culture medium; dominant lethal test in male rats with exposure to atmospheres containing 10 parts per million (ppm) or 400ppm NND; sperm abnormality test in male mice using the same exposure conditions; cytogenetic test in male and female rat bone marrow cells using the same exposure conditions or a single exposure of 7 hours duration; and sex linked recessive lethal test in Drosophila-melanogaster with exposure to an atmosphere of 400ppm for 2.25 hours. There was no increase in UDS in cells treated with NND nor were there effects attributable to NND in the dominant lethal test on pregnancy frequency, numbers of corpora lutea or implantations, or the frequency of early deaths. Abnormal sperm frequency was not affected, the frequencies of chromosomal aberrations were not increased in rat bone marrow cells, and sex linked recessive lethal frequency was not increased in Drosophila. The author concludes that NND was devoid of genetic effects.
NIOSH-Contract; Contract-210-78-0026; Screening-methods; Bioassays; Genetic-disorders; Mutagenesis; Toxicology
Final Contract Report
NTIS Accession No.
National Institute for Occupational Safety and Health
Inveresk Research International Limited, Musselburgh, Scotland
Page last reviewed: September 2, 2020
Content source: National Institute for Occupational Safety and Health Education and Information Division